Pipeline

August 27, 2018

Company	Drug/Device	Medical Condition	Status
Aravive Biologics, Inc.	AVB-S6-500	Platinum-resistant ovarian cancer	Granted Fast Track Designation by the FDA
Biohaven Pharma	BHV-0223	Social anxiety and public speaking anxiety disorders	Positive data from a proof-of-concept Phase III clinical trial
Sun Pharmaceutical Industries Ltd.	Cequa (cyclosporine ophthalmic solution) 0.09 percent	Keratoconjunctivitis sicca (dry eye)	Approval granted by FDA
Lion TCR Pte. Ltd.	LioCyx™	Relapsed liver cancer post-liver transplantation	Approval granted by Health Sciences Authority (HSA), Singapore, for multicenter Phase I/II clinical trial
Taiwan Liposome Company, Ltd.	TLC590, a proprietary BioSeizer™ liposomal formulation of ropivacaine	Postsurgical pain	Dosing of first patients in a Phase I/II trial
Teva Pharmaceuticals	Generic version of EpiPen Auto-Injector	Severe allergic reactions	Approval granted by the FDA
BeiGene Ltd.	Tislelizumab, an investigational anti-PD-1antibody, combined with chemotherapy as a potential first-line treatment	Stage IIIB or IV squamous non-small cell lung cancer (NSCLC)	Phase III clinical trial initiated
Eiger BioPharmaceuticals, Inc.	Avexitide (formerly exendin 9-39)	Post-bariatric surgical patients who experience post-bariatric hypoglycemia (PBH)	Completion of enrollment in Phase II clinical trial
Escalier Biosciences, BV	ESR-114 topical gel	Mild-to-moderate psoriasis	Phase I/IIa clinical trial initiated
Sangamo Therapeutics, Inc.	SB-525, a cDNA gene therapy candidate	Hemophilia A	Positive preliminary data from the Phase I/II clinical trial
ADC Therapeutics	ADCT-402 (loncastuximab tesirine)	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	Phase II clinical trial initiated
Alexion Pharmaceuticals, Inc.	ALXN1210, investigational long-acting C5 complement inhibitor	Paroxysmal nocturnal hemoglobinuria (PNH)	FDA accepted Biologics License Application (BLA) for approval
Merck & Co.	Keytruda in combination with Alimta (pemetrexed) and platinum chemotherapy as first-line treatment	Metastatic non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations	Granted approval by the FDA
SPR Therapeutics	SPRING endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation (PNS) Systems	Pain	Cleared by the FDA
Univision 360	Luminelle DTx Hysteroscopy System	Hysteroscopy and cystoscopy	Received 510(k) clearance from the FDA
Tolero Pharmaceuticals, Inc.	Combination therapy with AbbVie’s venetoclax and Tolero’s investigational agent	Relapsed/refractory acute myeloid leukemia (AML)	Tolero Pharmaceuticals and AbbVie partner for trial